{"product_id":"prct-ansoff-analysis","title":"(PRCT) PROCEPT BioRobotics Corporation ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis PROCEPT BioRobotics Corporation Ansoff Matrix Analysis clarifies the company’s growth options—market penetration, market development, product development, and diversification—and shows how its robotic surgical platforms can be expanded or adapted; the page includes a genuine preview\/sample so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand Aquablation use across the installed U.S. base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics had 78 of 130 AquaBeam systems in the U.S. at year-end 2021, so the fastest market penetration move is still to drive more Aquablation cases through the installed base. Each added procedure lifts high-margin disposable revenue, since the system needs recurring single-use tools for every case. That makes surgeon training, hospital utilization, and referral capture the key volume levers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvert more BPH patients from legacy surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquablation therapy targets men with benign prostatic hyperplasia and lower urinary tract symptoms, so PROCEPT BioRobotics Corporation can win share from legacy surgery inside the same BPH market. In 2024, the company reported revenue growth above 40%, helped by more installed systems and rising procedure volumes. Every conversion from TURP or laser surgery is direct market penetration, not a new-market bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaise surgeon credentialing in current accounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics can lift Market Penetration by credentialing more urologists and OR teams in current hospitals, since each trained user raises system use and case throughput. The company ended 2024 with over 500 AquaBeam systems installed, so deeper surgeon access inside the same accounts can scale utilization without adding new markets. More credentialed operators also lowers idle time and speeds repeat procedure adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIncrease utilization of current hospital placements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation can grow faster by pushing more cases through each installed robot, because higher utilization spreads the capital cost over more procedures and lifts recurring Aquablation therapy sales. In 2025, that penetration play matters even more as hospitals protect budgets and prefer platforms that improve OR economics without adding new capital spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore cases per robot\u003c\/li\u003e\n\u003cli\u003eLower cost per procedure\u003c\/li\u003e\n\u003cli\u003eHigher recurring consumables pull-through\u003c\/li\u003e\n\u003cli\u003eBetter hospital ROI and retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGrow repeat disposable sales per procedure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEach Aquablation case adds recurring disposable revenue, so more cases in the same hospital network lift sales without new system placements. In FY2024, PROCEPT BioRobotics Corporation reported revenue of $224.8 million, showing how procedure volume, not just hardware, drives the model. This is the clearest market penetration lever after the install base is in place.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore cases, same installed base.\u003c\/li\u003e\n\u003cli\u003eDisposable revenue repeats every procedure.\u003c\/li\u003e\n\u003cli\u003eCase growth scales margin and cash flow.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePROCEPT’s Growth Hinges on Driving More Aquablation Cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation’s Market Penetration strategy is to drive more Aquablation cases through its existing installed base. In 2024, revenue reached $224.8 million as procedure growth lifted recurring disposable sales. With over 500 AquaBeam systems installed by year-end 2024, deeper use of each system is the main near-term lever.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$224.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAquaBeam systems installed\u003c\/td\u003e\n\u003ctd\u003e500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePenetration lever\u003c\/td\u003e\n\u003ctd\u003eMore cases per system\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes PROCEPT BioRobotics Corporation’s growth strategy across existing and new products and markets using the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear PROCEPT BioRobotics Ansoff Matrix to quickly align growth priorities across products and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, vetted bibliography tying each Ansoff growth path for PROCEPT BioRobotics to traceable primary and secondary sources for fast, defensible decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtend AquaBeam beyond the U.S.-heavy base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquaBeam is already deployed outside the U.S., but the U.S. still makes up the majority of PROCEPT BioRobotics Corporation systems, so more non-U.S. sales use the same product, not a new one. In FY2025, that makes this a clear market development move: take one cleared platform into more geographies. The play is expansion, not redesign.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdd more non-U.S. hospital systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation already has a non-U.S. footprint, which shows its AQUABEAM platform can be adopted outside the United States. Adding more hospital systems in those same markets is a direct market development move: same therapy, more sites, wider reach. It also scales a recurring capital-plus-disposable model without changing the core product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroaden access in new country markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation already sells beyond one country, so expanding AquaBeam and Aquablation into new national markets fits the Ansoff market development play. The product stays the same; only the geography changes, which can scale revenue without changing the core device. That matters in a urology market where approved, hospital-ready systems can move faster than new products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReach additional BPH referral channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation can expand Aquablation by building referral ties with community urologists and primary care clinicians, opening new patient sources for men with BPH-related lower urinary tract symptoms. This is classic new-market access with an existing product: the therapy stays the same, but the funnel widens beyond large academic centers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore referrals, same Aquablation therapy\u003c\/li\u003e\n\u003cli\u003eTargets men with BPH-LUTS\u003c\/li\u003e\n\u003cli\u003eUses community urologists and clinicians\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat matters because BPH is common in older men, so even small referral gains can lift procedure volume and recurring capital sales for PROCEPT BioRobotics Corporation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIncrease presence in additional care settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation can place the same BPH therapy in more urology offices, ASCs, and hospital outpatient sites, so it grows addressable demand without changing the product. BPH affects about 50% of men in their 50s and up to 90% in their 80s, so each new care setting widens access to the same patient pool.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame therapy, more treatment sites\u003c\/li\u003e\n\u003cli\u003eExpands geographic reach and channels\u003c\/li\u003e\n\u003cli\u003eUses current product, not new R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis market development move can lift procedure volume faster than product change alone, because one installed system can serve more referral paths and more prostate procedure accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePROCEPT’s Growth Story Is Global Expansion, Not New Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation’s market development is the same AquaBeam\/Aquablation system pushed into more countries, care sites, and referral channels. In FY2025, the U.S. still drove most systems, so the growth lever is geographic and channel expansion, not new product design.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003cth\u003eMeaning\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-U.S. sales\u003c\/td\u003e\n\u003ctd\u003eMinority of systems\u003c\/td\u003e\n\u003ctd\u003eRoom to expand abroad\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBPH market\u003c\/td\u003e\n\u003ctd\u003e50% of men in 50s; 90% in 80s\u003c\/td\u003e\n\u003ctd\u003eLarge same-product demand pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003ePROCEPT BioRobotics Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvance the next-generation robotic platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation’s product development strategy upgrades the AquaBeam Robotic System that delivers Aquablation therapy, keeping the company in the same urology market while refreshing the platform. The focus is clear: improve precision, workflow, and surgeon usability on a single core system.\u003c\/p\u003e\n\u003cp\u003eThis is a one-product-platform bet, with 2 core offerings tied together: AquaBeam Robotic System and Aquablation therapy. Next-gen hardware can lift repeat use, support higher procedure volumes, and defend share without moving outside urology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImprove image guidance and planning software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImprove image guidance and planning software fits AquaBeam’s image-guided workflow, so current users can get better targeting without changing the core system. Smarter imaging and pre-op planning can cut setup friction and support more consistent treatment delivery. That makes the upgrade a low-friction way to deepen adoption inside the existing user base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand disposable and accessory offerings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation’s procedure-led model naturally supports recurring consumables, because each Aquablation case can pull through disposable and accessory items. Adding new single-use components around the installed base is product development: it grows value in the same market, not a new one. This also deepens stickiness, since every added accessory can lift case economics and repeat revenue per system.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSimplify Aquablation workflow steps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSimplifying Aquablation workflow steps at PROCEPT BioRobotics Corporation fits a practical product development move: hospitals want faster setup, and surgeons want less friction in the room. The Company Name platform already sits in a procedure-driven market, so small usability gains can matter more than big hardware changes when adoption depends on OR time and repeat use.\u003c\/p\u003e\n\u003cp\u003eThat matters because the system’s value is tied to efficiency, consistency, and throughput in current accounts, where even modest reductions in prep time can help defend utilization. Product refinements that make the Aquablation process easier to learn and quicker to run can support higher conversion inside installed sites without changing the core therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower setup time improves OR efficiency.\u003c\/li\u003e\n\u003cli\u003eCleaner steps help surgeon adoption.\u003c\/li\u003e\n\u003cli\u003eUsability gains support existing accounts.\u003c\/li\u003e\n\u003cli\u003eLow-risk path for platform growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroaden clinical evidence for the platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBroader clinical evidence for PROCEPT BioRobotics Corporation can deepen physician trust in Benign Prostatic Hyperplasia treatment and support wider use of the same platform. More peer-reviewed data helps prove consistent outcomes, lower retreatment risk, and clearer patient selection, which strengthens product positioning in the core market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports physician adoption in BPH\u003c\/li\u003e\n\u003cli\u003eReinforces clinical outcome claims\u003c\/li\u003e\n\u003cli\u003eImproves positioning without new markets\u003c\/li\u003e\n\u003cli\u003eFits product-development strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePROCEPT Boosts Aquablation with Smarter Imaging and Simpler Workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation’s product development stays on one core urology platform: AquaBeam Robotic System plus Aquablation therapy. The next step is better imaging, planning, workflow, and single-use accessories, which can lift adoption in the same market without a new category.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct move\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImaging and software upgrades\u003c\/td\u003e\n\u003ctd\u003eBetter targeting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkflow simplification\u003c\/td\u003e\n\u003ctd\u003eFaster OR use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccessories and disposables\u003c\/td\u003e\n\u003ctd\u003eHigher repeat pull-through\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo disclosed non-urology product line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of July 2026, PROCEPT BioRobotics Corporation still relies on one core platform, Aquablation, for urology and BPH, with 0 disclosed non-urology product lines. That means diversification is weak: the company’s revenue base stays tied to 1 specialty and 1 procedure set, so any true expansion beyond urology remains unproven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore focus remains Aquablation for BPH\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics’ diversification is still low: Aquablation for BPH remains the flagship and the main revenue engine. In FY2024, Company Name reported $199.8 million in revenue, up 61% year over year, and the business identity still centers on robotic, image-guided treatment of male BPH. That is concentration, not broad spread across new markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal growth still uses the same therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation’s international push still centers on the same AquaBeam and Aquablation platform, so it is geographic expansion, not product diversification. That matters because the company is still selling one therapy family into the same urology use case, with no new category added. In FY2025, the core story remains the same: more countries, same treatment, same clinical platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRevenue remains tied to systems and disposables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation still relies on one therapy: urology. Its system placements and procedure-linked disposables are different revenue streams, but both depend on Aquablation adoption, so this is not true diversification. In FY2025, that concentration kept growth tied to the same clinical and reimbursement cycle.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo streams, one product category\u003c\/li\u003e\n\u003cli\u003eSystems drive installed base\u003c\/li\u003e\n\u003cli\u003eDisposables depend on procedures\u003c\/li\u003e\n\u003cli\u003eUrology concentration stays high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdjacency stays within the same specialty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation still looks urology-led: its core platform is Aquablation therapy for benign prostatic hyperplasia, so the growth path stays inside the same specialty. There is no clear evidence here of a separate new market with a separate new product, so diversification is not a major visible strategy.\u003c\/p\u003e\n\u003cp\u003eThat means adjacency, not true diversification, is the better read. Any expansion still appears tied to robotic urology workflows, where PROCEPT BioRobotics Corporation can deepen use in the same clinician base and care setting.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore market: urology\u003c\/li\u003e\n\u003cli\u003eCore product: Aquablation\u003c\/li\u003e\n\u003cli\u003eNew market not supported\u003c\/li\u003e\n\u003cli\u003eNew product not supported\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePROCEPT Still Tied to One Therapy in FY2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePROCEPT BioRobotics Corporation’s diversification remains weak in FY2025: Aquablation still drives the business, with $199.8 million FY2024 revenue and no disclosed non-urology product lines. International growth adds geography, not a new product market, so the company is still concentrated in 1 therapy family.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\/FY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore therapy\u003c\/td\u003e\n\u003ctd\u003eAquablation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$199.8M FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-urology lines\u003c\/td\u003e\n\u003ctd\u003e0 disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234809454857,"sku":"prct-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/prct-ansoff-matrix.webp?v=1785729048","url":"https:\/\/dcfanalyst.com\/products\/prct-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}